Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.J&J and GNS sign cancer drug development deal
Under the agreement, Johnson & Johnson Pharmaceutical R&D (J&JPRD) will use proprietary pathway inference technology and data-driven computer models from Gene Network Sciences (GNS) to help determine the
Under the agreement, Johnson & Johnson Pharmaceutical R&D (J&JPRD) will use proprietary pathway inference technology and data-driven computer models from Gene Network Sciences (GNS) to help determine the
However, although the study of Xyotax in combination with carboplatin in non-small cell lung cancer (NSCLC), known as STELLAR 3, missed its primary endpoint, it did meet statistical
According to the results, styrylquinolines (SQLs) are synergistic with reverse transcriptase inhibitors, namely zidovudine (GlaxoSmithKline’s Retrovir) and nevirapine (Boehringer Ingelheim’s Viramune), and with another family of integrase inhibitors,
In the phase I/II clinical trial, patients received MDX-010 every three weeks, plus high dose IL-2 therapy. Study results show that eight of 36 patients with metastatic melanoma
The two-stage design phase II CoFactor clinical trial included patients with surgically incurable, metastatic colon or rectal adenocarcinoma. CoFactor is a biomodulator developed to enhance the activity of
John West, Solexa Ltd’s chief executive, has assumed the chief executive position of the combined company, which will be headquartered in California. The board of Solexa Inc will
Evotec Neurosciences (ENS) discovers and develops therapeutics for the treatment of Alzheimer’s disease and other central nervous system (CNS) disorders with high unmet medical needs. The acquisition will
External Independent Data Monitoring Committee (IDMC) analyses of both phase III trials exceeded the pre-specified value for stopping the trials, as the IDMC found a statistically significant improvement
The financing will take place in two closings. In the first closing, investors will purchase $2,000,000 of Series D preferred stock and warrants. The second closing, for which
Previous studies have shown that aspirin resistance is associated with triple the risk of heart attack, stroke and death. Once patients are tested and identified as aspirin resistant,